Entera Bio Submits Streamlined Phase 3 Protocol for Osteoporosis Drug EB613, Accelerating Trial Timeline

summarizeSummary

Entera Bio submitted a streamlined Phase 3 protocol for its oral osteoporosis drug EB613 to the FDA, featuring a shorter primary endpoint and direct use of a commercial formulation, which is expected to accelerate topline data by one year.

check_boxKey Events

• Phase 3 Protocol Submitted to FDA

  Entera Bio submitted a streamlined Phase 3 protocol for EB613 to the FDA, initiating the registrational trial for postmenopausal women with osteoporosis.

• Accelerated Timeline for Topline Data

  Topline data from the Phase 3 study is now anticipated in the second half of 2028, approximately one year earlier than previously expected due to a shorter 12-month primary endpoint.

• Streamlined Trial Design

  The Phase 3 study will use a 12-month total hip BMD primary endpoint and directly advance the final single-tablet commercial formulation (Next-Gen EB613), eliminating the need for future bridging studies.

auto_awesomeAnalysis

This filing marks a significant positive development for Entera Bio, as it outlines an accelerated and de-risked path for its lead oral osteoporosis candidate, EB613. The FDA submission of a streamlined Phase 3 protocol, including a shorter 12-month primary endpoint and the direct use of the final commercial formulation, is expected to bring topline data forward by approximately one year to the second half of 2028. This strategic move reduces development time and costs, enhancing the drug's potential to reach the market sooner and address a significant unmet medical need in postmenopausal osteoporosis. Investors should monitor FDA feedback and the initiation of the Phase 3 study.